Theranostic Nanomedicine for Malignant Gliomas

44Citations
Citations of this article
75Readers
Mendeley users who have this article in their library.

Abstract

Brain tumors mainly originate from glial cells and are classified as gliomas. Malignant gliomas represent an incurable disease; indeed, after surgery and chemotherapy, recurrence appears within a few months, and mortality has remained high in the last decades. This is mainly due to the heterogeneity of malignant gliomas, indicating that a single therapy is not effective for all patients. In this regard, the advent of theranostic nanomedicine, a combination of imaging and therapeutic agents, represents a strategic tool for the management of malignant brain tumors, allowing for the detection of therapies that are specific to the single patient and avoiding overdosing the non-responders. Here, recent theranostic nanomedicine approaches for glioma therapy are described.

Cite

CITATION STYLE

APA

d’Angelo, M., Castelli, V., Benedetti, E., Antonosante, A., Catanesi, M., Dominguez-Benot, R., … Cimini, A. (2019, November 14). Theranostic Nanomedicine for Malignant Gliomas. Frontiers in Bioengineering and Biotechnology. Frontiers Media S.A. https://doi.org/10.3389/fbioe.2019.00325

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free